SCHEMBL5429189

SCHEMBL5429189

Cn1cc(-c2nccc(Oc3ccc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)cc3)n2)cn1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.73
BRAF P15056 4/20 0.57
RAF1 P04049 2/20 0.56
CDK8 P49336 2/20 0.54
MEN1 O00255 1/20 0.54
PLK4 O00444 1/20 0.54
CIT O14578 1/20 0.54
AURKA O14965 1/20 0.54
MUSK O15146 1/20 0.54
EPHB6 O15197 1/20 0.54
MAPK13 O15264 1/20 0.54
MLNR O43193 1/20 0.54
MAP3K7 O43318 1/20 0.54
RIPK2 O43353 1/20 0.54
DYRK3 O43781 1/20 0.54
PDE6D O43924 1/20 0.54
NR1I2 O75469 1/20 0.54
STK10 O94804 1/20 0.54
CDK14 O94921 1/20 0.54
ABCB11 O95342 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5431936 0.93 KDR (0.66) KDRBRAFCDK8NTRK1RET
SCHEMBL5335483 0.92 KDR (0.74) KDRBRAFRAF1RIPK2ABCB11
SCHEMBL5451158 0.92 KDR (0.65) KDRBRAFRAF1RIPK2ABCB11
SCHEMBL5333938 0.87 KDR (0.54) KDRBRAFCDK8AURKANTRK1
SCHEMBL5333026 0.87 KDR (0.63) KDRBRAFRAF1RIPK2ABCB11
SCHEMBL5345816 0.86 KDR (0.65) KDRBRAFCDK8PLK4AURKA
SCHEMBL5345812 0.85 KDR (0.64) KDRRAF1CSF1RPDGFRBTEK
SCHEMBL17179246 0.85 KDR (1.00) KDRBRAFRAF1CDK8MEN1
SCHEMBL5460315 0.84 KDR (0.77) KDRBRAFRAF1CDK8PDGFRB
SCHEMBL17179270 0.83 KDR (1.00) KDRBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 KDR 555/4885BRAF 1/4885RAF1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.